Study of Brimonidine and Timolol Ophthalmic Solution With Latanoprost Compared With Latanoprost in Glaucoma Patients

• Status: Terminated
• Trial end date: 2012-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the safety and efficacy of patients switched from latanoprost monotherapy to a combination therapy of latanoprost with COMBIGAN® (brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution) for chronic angle closure glaucoma.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Brimonidine Tartrate; Brimonidine Tartrate, Timolol Maleate Drug Combination; Latanoprost; Ophthalmic Solutions; Pharmaceutical Solutions; Timolol

Criteria

Inclusion Criteria:

• Patient has been administering latanoprost eye drops in affected eye(s) for at least 12 weeks prior to study

• Patient must have at least partially responded to latanoprost and requiring further IOP lowering eye drops

• Diagnosis of chronic angle-closure glaucoma

• Patients using COMBIGAN® in the past must not have been discontinued due to adverse events or lack of efficacy.

Exclusion Criteria:

• Known allergy or hypersensitivity to COMBIGAN®

• Corneal abnormalities that would preclude accurate IOP readings

• Any other active ocular disease other than glaucoma or ocular hypertension

• Ocular surgery within the past 3 months.